Plasma from COVID-19 survivors tested as treatment for the critically ill
NCT ID NCT04376034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving plasma (the liquid part of blood) from people who recovered from COVID-19 could help critically ill patients fight the virus. The plan was to collect plasma from up to 240 recovered donors and give it to sick patients. However, the plasma donation part was not completed because the state lacked the needed equipment and approvals. The study still tracked how long it took to identify donors and how well patients survived after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
117 people
The number who actually took part.
- Started
-
Apr 2020
- Finished
-
Apr 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
31 days and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: (NOTE: It is important to note that West Virginia, as a state, does not have any entity with the required FDA registration or licensure, nor the necessary on-site equipment, to collect convalescent plasma for the purpose of plasma transfusion. Therefore, the plasma donation portion of this study was not completed). * Plasma donation: 1. Prior diagnosis of COVID-19 documented by a laboratory test 1. Abbott RealTime SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) test on the Abbott m2000 System (Inpatient WVU testing) 2. Other testing methods and vendors using FDA approved detection methods of SARS-CoV-2 under the Emergency Use Authorization (EUA) 2. Complete resolution of symptoms at least 28 days prior to donation 3. Complete resolution of symptoms for at least 14 days with negative repeat COVID-19 testing approved by the FDA EUA 4. Female donors age 18+ that have never been pregnant or negative for HLA antibodies 5. Male donors age 18+ 6. Negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. A partial list of available tests can be accessed at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations. 7. Defined SARS-CoV-2 neutralizing antibody titers, if testing can be conducted (e.g., of at least 1:1602, 1:360 up to 1:640 is preferred. In shortage case 1:80 is acceptable) 8. At least or greater than 50kg of weight * Plasma Recipients: 1. Individuals of any age above 30 days of life, sex, or pregnancy status suffering from confirmed COVID19 and in rapid progression, severe or critical condition meeting the FDA IND guidelines. 2. Must have laboratory confirmed COVID19 3. Must have severe or immediately life-threatening COVID19 4. Must provide informed consent/assent Exclusion Criteria: * Plasma donation: 1. Individuals that do not meet the requirement from the American Red Cross for plasma donation or equivalent 2. Individuals plasma that has not passed safety screening after procurement by the American Red Cross for plasma donation or equivalent * Plasma Recipients 1. Individuals with COVID19 who are not in clinical concern for rapid progression, severe or critical condition 2. Individuals who are in critical condition that are not confirmed to have COVID19 3. Individuals with known Selective IgA Deficiency, that has not been found to be absent of anti-IgA antibodies
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronavirus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
WVU Medicine
Morgantown, West Virginia, 26506, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- COVID-19's hidden toll: muscle wasting in the ICU
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- Can a mild case of COVID-19 harm your kidneys? urine tests may hold the answer
- When the immune system Can't fight back: tracking three respiratory viruses
- The household maze: how does COVID-19 move between family members?